Zhejiang Jolly Pharmaceutical Co.,LTD

SZSE:300181 Stock Report

Market Cap: CN¥10.5b

Zhejiang Jolly PharmaceuticalLTD Future Growth

Future criteria checks 5/6

Zhejiang Jolly PharmaceuticalLTD is forecast to grow earnings and revenue by 23.3% and 22.5% per annum respectively. EPS is expected to grow by 23% per annum. Return on equity is forecast to be 23.3% in 3 years.

Key information

23.3%

Earnings growth rate

23.0%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate22.5%
Future return on equity23.3%
Analyst coverage

Low

Last updated21 Nov 2024

Recent future growth updates

No updates

Recent updates

Does Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Deserve A Spot On Your Watchlist?

Nov 28
Does Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Deserve A Spot On Your Watchlist?

Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump

Oct 17
Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump

These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely

Oct 06
These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Aug 30
It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Jul 29
We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08
A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01
There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Earnings and Revenue Growth Forecasts

SZSE:300181 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,0858615008482
12/31/20253,2806863846932
12/31/20242,6055482576052
9/30/20242,522518116279N/A
6/30/20242,359481245381N/A
3/31/20242,120428145294N/A
12/31/20231,942383157288N/A
9/30/20231,926356162349N/A
6/30/20231,922336137310N/A
3/31/20231,86130291245N/A
1/1/20231,805273141319N/A
9/30/20221,72325258260N/A
6/30/20221,65522875290N/A
3/31/20221,55720474290N/A
1/1/20221,457179104252N/A
9/30/20211,400158234319N/A
6/30/20211,322145269336N/A
3/31/20211,238122267327N/A
12/31/20201,09189221280N/A
9/30/20201,02449180222N/A
6/30/20209492982118N/A
3/31/202090126112148N/A
12/31/20199112688129N/A
9/30/201985934109160N/A
6/30/20197671439131N/A
3/31/201976423-5104N/A
12/31/201873021-7678N/A
9/30/201860920-12536N/A
6/30/201862931N/A102N/A
3/31/201864743N/A20N/A
12/31/201767945N/A8N/A
9/30/201780449N/A114N/A
6/30/201781463N/A21N/A
3/31/201783059N/A54N/A
12/31/201684072N/A58N/A
9/30/201681986N/A22N/A
6/30/201681087N/A78N/A
3/31/201672085N/A112N/A
12/31/201567185N/A97N/A
9/30/2015657103N/A16N/A
6/30/2015620111N/A-18N/A
3/31/2015572107N/A-39N/A
12/31/2014515103N/A14N/A
9/30/201445794N/A13N/A
6/30/201444090N/A35N/A
3/31/201443185N/A42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300181's forecast earnings growth (23.3% per year) is above the savings rate (2.8%).

Earnings vs Market: 300181's earnings (23.3% per year) are forecast to grow slower than the CN market (25.4% per year).

High Growth Earnings: 300181's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300181's revenue (22.5% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 300181's revenue (22.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300181's Return on Equity is forecast to be high in 3 years time (23.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 21:01
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Jolly Pharmaceutical Co.,LTD is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhu ChenCitic Securities Co., Ltd.
Mingrui WangEverbright Securities Co. Ltd.
Suqing HuangEverbright Securities Co. Ltd.